We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Innovative LAMP Molecular Diagnostic Test Diagnoses Chagas Disease in Newborns

By LabMedica International staff writers
Posted on 04 Jul 2024
Print article
Image: The LAMP molecular diagnostic test could be used to detect T. cruzi infection -responsible for Chagas disease- in newborns (Photo courtesy of ISGlobal)
Image: The LAMP molecular diagnostic test could be used to detect T. cruzi infection -responsible for Chagas disease- in newborns (Photo courtesy of ISGlobal)

T. cruzi infection leads to Chagas disease in newborns, with vertical (congenital) transmission accounting for 20% of new cases. This transmission occurs when an infected mother transfers the parasite to her baby during pregnancy. Consequently, early detection of the parasite in both women and newborns is a critical public health concern. However, the challenge lies in the absence of simple, rapid, and reliable testing methods. In affluent nations like Spain, newborn diagnosis can be conducted using PCR, but this method is costly and requires trained professionals. In regions where the disease is endemic, typically two microscopy tests are administered—one at birth and another at two months. These tests have low sensitivity and are usually followed by a serological test months later to identify antibodies against the parasite. The multiple tests and the delay between them heighten the risk of delayed treatment for affected children. Now, an innovative test combining a DNA extraction system, inspired by a modified 3D printer, with loop-mediated isothermal molecular amplification (LAMP), could potentially detect T. cruzi infection in newborns.

This was the conclusion of a group of researchers at the Barcelona Institute for Global Health (ISGlobal, Barcelona, Spain) after a study conducted in Bolivia’s Chaco region, a hotspot for Chagas disease. In this study published in the journal The Lancet Microbe, the team tested a novel diagnostic method that integrates the LAMP technique with a 3D printer modified to extract DNA from a small blood sample. The effectiveness of this method was benchmarked against PCR and traditional diagnostic approaches (microscopy and serology). The study tracked 224 infants born to mothers seropositive for T. cruzi over eight months, identifying 23 cases of congenital transmission—nine detected by microscopy at birth and an additional 14 by serology eight months later.

The LAMP test successfully identified 13 out of the 23 cases early in the process, detecting four more cases than microscopy and nearly matching the 14 cases detected by PCR. This indicates that LAMP’s sensitivity surpasses microscopy and is comparable to PCR. An added benefit of the LAMP test is its potential cost-effectiveness and minimal infrastructure needs. In accordance with national guidelines for diagnosing and treating congenital Chagas disease, all detected cases were treated successfully, underscoring the vital role of early detection and intervention. The research team emphasized that this study served as a proof of concept for the LAMP diagnostic test’s viability, suggesting that further trials should be conducted on a broader scale and in more centers. If its efficacy is validated, this test could also be employed to detect acute infections in adults or to evaluate the efficacy of treatments.

"In endemic regions, it would be very useful to have a simple, rapid and sensitive test to detect the parasite in newborns, when treatment is most effective," said Julio Alonso Padilla, researcher at ISGlobal.

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
Magnetic Bead Separation Modules

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.